Brain tumor study looks at tiny molecule as possible clue
NCT ID NCT01849952
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at a tiny molecule called microRNA-10b in people with brain tumors called gliomas. Researchers wanted to see if higher levels of this molecule could help predict how the disease might progress or how long patients might live. The study was stopped early, but it aimed to better understand different types of gliomas and possibly find new ways to treat them.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
94 people
The number who actually took part.
- Started
-
Oct 2013
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients seen in the clinic who are going to be treated with surgery, radiation and medical therapy for gliomas will be eligible for the study.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion/Exclusion Criteria: * 18 years of age * Brain tumor(s) to be resected for clinical reasons. * Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV. * Adequate tissue available for processing as determined by Pathology. * Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment. * Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anaplastic astrocytoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
University of Vermont
Burlington, Vermont, 05405, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental therapy aims to turn brain tumors against themselves
- Can doctors watch brain metastases instead of zapping them?
- Radioactive tracer lights up Oxygen-Starved brain tumors
- Can a common virus vaccine help fight brain cancer?
- Radioactive tiles target brain tumors in frail patients
- Breathing CO2 during brain scans could reveal hidden tumor disruption